IN THE SPECIFICATION

Please delete the first full paragraph on page 1, lines 5-6, and replace with the following:

This application is a continuation of U.S. Patent Application Serial No. 09/705,581, filed November 2, 2000, now U.S. Patent 6,673,777, which is a divisional of U.S. Patent Application Serial No. 08/970,793, filed November 14, 1997, now U.S. Patent 6,143,728, which claims benefit of U.S. Provisional Application Serial No. 60/031,061, filed November 15, 1996. The entirety of these applications are incorporated herein by reference.

No new matter is believed to be added. Entry is respectfully requested.

Please amend the fourth full paragraph at page 1, lines 25-33, as follows:

HIV-infection is pandemic and HIV-associated diseases represent a major world health problem. Although considerable effort is being put into the design of effective therapeutics, currently no curative anti-retroviral drugs against AIDS exist. For example, virally encoded reverse transcriptase has been one focus of drug development. A number of reverse-transcriptase-targeted drugs, including 2',3'-dideoxynucleoside analogs such as AZT, ddI, ddC, 3TC, and d4T have been developed which have been shown to been active against HIV (Mitsuya et al., *Science* 249:1533-1544, [[1991]] 1990). While beneficial, these nucleoside analogs are not curative (~~Lander~~ Larder et al., *Science* 243:1731-1734, 1989). In addition, the drugs often cause toxic side effects such as bone marrow suppression, vomiting, and liver function abnormalities.

Please amend the specification by replacing the Sequence Listing pages 22-23 with the attached substitute Sequence Listing. This substitute Sequence Listing incorporates the amendments to the Sequence Listing made in the Preliminary Amendment filed with the parent

application Serial No. 09/705,581 (now U.S. Patent 6,673,777) originally filed on November 2, 2000 (a copy of which was filed with this specification, along with the accompanying Declaration pursuant to 37 CFR §1.132 on November 2, 2000).